Share of the population living with HIV receiving antiretroviral therapy in Netherlands

Netherlands: Share of the population living with HIV receiving antiretroviral therapy was 88.6% in 2023. ◆ Volatile

Latest (2023)
88.6%
Change on year
up 0.8%
World rank
22nd
of 149 countries
All-time high
88.6%
in 2023
All-time low
0.0%
in 1990
Years of data
34
1990–2023

Share of the population living with HIV receiving antiretroviral therapy in Netherlands, 1990–2023

0204060801990200620231990: 0 %1991: 0 %1992: 0 %1993: 0 %1994: 0 %1995: 0 %1996: 28.7 %1997: 37.7 %1998: 41.3 %1999: 43.8 %2000: 45.5 %2001: 48.6 %2002: 50.9 %2003: 52 %2004: 52.8 %2005: 53.3 %2006: 54.1 %2007: 55.8 %2008: 58.9 %2009: 61.8 %2010: 65.1 %2011: 67.6 %2012: 70.4 %2013: 73.8 %2014: 77.3 %2015: 80 %2016: 81.8 %2017: 83.7 %2018: 85.2 %2019: 86.7 %2020: 87.2 %2021: 87.4 %2022: 87.9 %2023: 88.6 %

Source: Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data. Measured in %.

Analysis

In 2023, share of the population living with hiv receiving antiretroviral therapy in Netherlands stood at 88.6%. That is the highest value across all 34 years on record.

The figure is up 0.8% on the previous year and up 20.1% over ten years.

Over the whole period, share of the population living with hiv receiving antiretroviral therapy in Netherlands peaked at 88.6% in 2023 and was at its lowest, 0.0%, in 1990.

That places Netherlands 22nd out of 149 countries with data for 2023, putting it in the top quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Share of the population living with HIV receiving antiretroviral therapy in Netherlands, year by year

Annual values for Share of the population living with HIV receiving antiretroviral therapy in Netherlands, 1990 to 2023.
Year % Change
1990 0.0% —
1991 0.0% —
1992 0.0% —
1993 0.0% —
1994 0.0% —
1995 0.0% —
1996 28.7% —
1997 37.7% +31.6%
1998 41.3% +9.5%
1999 43.8% +6.0%
2000 45.5% +4.1%
2001 48.6% +6.8%
2002 50.9% +4.8%
2003 52.0% +2.1%
2004 52.8% +1.6%
2005 53.3% +0.9%
2006 54.1% +1.5%
2007 55.8% +3.2%
2008 58.9% +5.5%
2009 61.8% +4.9%
2010 65.1% +5.2%
2011 67.6% +3.9%
2012 70.4% +4.1%
2013 73.8% +4.8%
2014 77.3% +4.8%
2015 80.0% +3.4%
2016 81.8% +2.3%
2017 83.7% +2.3%
2018 85.2% +1.8%
2019 86.7% +1.8%
2020 87.2% +0.6%
2021 87.4% +0.2%
2022 87.9% +0.5%
2023 88.6% +0.8%

Netherlands compared with similar countries

  • Netherlands's 88.6% is above the median for high income countries, which is 79.3%, 1.1× the median. (42 countries reporting)
  • Netherlands's 88.6% is above the median for Europe & Central Asia, which is 82.9%, 1.1× the median. (34 countries reporting)

Biggest year-on-year movements

Years where Share of the population living with HIV receiving antiretroviral therapy in Netherlands changed far more than this series normally does. A large move can be a real event or a change in how the figure was measured — the source note below says who published it.

YearChange FromTo
1997 +31.6% 28.7% 37.7%

Averages by decade

DecadeAverage LowestHighest Years
1990s 15.1% 0.0% 43.8% 10
2000s 53.4% 45.5% 61.8% 10
2010s 77.2% 65.1% 86.7% 10
2020s 87.8% 87.2% 88.6% 4

Countries ranked near Netherlands

  1. 19 Switzerland 89.8% compare
  2. 20 Ireland 89.3% compare
  3. 21 Romania 89.2% compare
  4. 23 Ethiopia 88.3% compare
  5. 24 Iceland 88.2% compare
  6. 25 Belgium 88.1% compare

See the full ranking of 149 places →

More reference data data for Netherlands

All data for Netherlands →

Frequently asked questions

What is share of the population living with hiv receiving antiretroviral therapy in Netherlands?
Share of the population living with hiv receiving antiretroviral therapy in Netherlands was 88.6% in 2023, according to Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data.
What is the highest share of the population living with hiv receiving antiretroviral therapy recorded in Netherlands?
The highest recorded value was 88.6% in 2023.
What is the lowest share of the population living with hiv receiving antiretroviral therapy recorded in Netherlands?
The lowest recorded value was 0.0% in 1990.
How does Netherlands rank for share of the population living with hiv receiving antiretroviral therapy?
Netherlands ranks 22nd out of 149 countries with data for 2023.
Is share of the population living with hiv receiving antiretroviral therapy rising or falling in Netherlands?
Over the last ten years it is up 20.1%. The long-run trend across the full record is volatile.
Where does this Netherlands data come from?
The figures come from Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as part of Share of the population living with HIV receiving antiretroviral therapy. Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 34 observations, free to reuse under CC BY 4.0 (Our World in Data).

Share, cite or embed this page

Cite this page

Share of the population living with HIV receiving antiretroviral therapy in Netherlands. Statizoid, drawing on Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data. Retrieved 29 September 2026, from https://reference.statizoid.com/stat/gap-to-reaching-the-target-of-art/netherlands/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (Our World in Data); please keep the attribution.

<a href="https://reference.statizoid.com/stat/gap-to-reaching-the-target-of-art/netherlands/">Share of the population living with HIV receiving antiretroviral therapy in Netherlands</a> — Statizoid

About this data

Indicator
Share of the population living with HIV receiving antiretroviral therapy
Unit
%
Source
Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data
Licence
CC BY 4.0 (Our World in Data)
Coverage
149 places, 5,062 data points, 1990–2024
Last refreshed

Percentage of individuals diagnosed with HIV who are currently receiving antiretroviral therapy. This is the central estimate.